Table 1.
Clinicopathological characteristics of study population from TCGA and our data.
| Our data | TCGA data | ||||||
|---|---|---|---|---|---|---|---|
| Type A, AB, B1, B2 (n=8)* | Type B3 (n=9) | Type C (n=17) | Type A, AB, B1, B2 (n=97)* | Type B3 (n=15) | Type C (n=11) | ||
| Gender | Male | 6 | 8 | 13 | 53 | 6 | 4 |
| Female | 2 | 1 | 4 | 44 | 9 | 7 | |
| Age | Median | 58.5 | 54 | 55 | 57.5 | 62 | 65 |
| Range | 33-73 | 39-60 | 16-66 | 17-84 | 40-71 | 44-78 | |
| Smoking status | Smoker | 3 | 3 | 8 | NP | NP | NP |
| Non-smoker | 5 | 6 | 9 | NP | NP | NP | |
| Masaoka stage | I | 3 | 0 | 0 | NP | NP | NP |
| II | 3 | 5 | 1 | NP | NP | NP | |
| III | 2 | 4 | 10 | NP | NP | NP | |
| IV | 0 | 0 | 6 | NP | NP | NP | |
| TNM stage | I | 8 | 6 | 2 | NP | NP | NP |
| II | 0 | 0 | 4 | NP | NP | NP | |
| III | 0 | 3 | 7 | NP | NP | NP | |
| IV | 0 | 0 | 4 | NP | NP | NP | |
| Neoadjuavant therapy | CT | 0 | 0 | 0 | 2 | 0 | 0 |
| RT | 0 | 1 | 0 | ||||
| CT+RT | 0 | 0 | 0 | ||||
| Adjuavant therapy | CT | 0 | 1 | 6 | 26 | 8 | 5 |
| RT | 1 | 6 | 1 | 1 | 0 | 2 | |
| CT+RT | 0 | 0 | 5 | 0 | 2 | 1 | |
CT, hemotherapy; RT, radiotherapy; NP, Not provided.
*including mixed type, A/B1, B1/B2.